Skip to main content


On September 21, 2021, the Association for Accessible Medicines (AAM), the trade association of generic and biosimilar manufacturers, released topline findings from its forthcoming 2021 U.S. Generic & Biosimilar Medicines Savings Report highlighting the value of generic and biosimilar drugs. Read More ›

Adoption of biosimilars continues to rise in the United States, but oncologists’ knowledge regarding these agents has not kept pace, according to data presented at the virtual 2021 American Society of Clinical Oncology (ASCO) Quality Care Symposium. Read More ›

On July 1, 2021, 28 patient advocacy groups submitted a letter demonstrating their support for H.R. 2815, also known as the Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act, which aims to increase Medicare reimbursement for health systems that prescribe biosimilars to patients. Read More ›

Rapid adoption of FDA-approved biosimilars is feasible, measurable, and scalable—and pharmacists should lead the charge, according to data presented at the virtual 2021 American Society of Clinical Oncology Quality Care Symposium. Read More ›

The advent of biologic drugs has had a significant impact on the management of patients with cancer. However, the high costs associated with these agents can hinder treatment access for many patients and place a significant burden on healthcare systems. Read More ›

Biosimilars have the potential to create a more sustainable healthcare environment by offering substantial cost-savings and expanding patient access to life-saving therapies. Read More ›

On September 20, 2021, the FDA announced the availability of its revised final guidance for industry on biosimilar development and the Biologics Price Competition and Innovation Act of 2009 (BPCI Act). Read More ›

Febrile neutropenia (FN) is a serious side effect of many cancer treatments and can lead to severe infection and sepsis with potentially fatal consequences. Read More ›

Due to the COVID-19 pandemic, the year 2020 has witnessed unprecedented changes in the practice of medicine and dissemination of treatment advances presented in scientific forums. Read More ›

The totality of evidence generated from comparative systematic stepwise assessment of HD201 and trastuzumab reference in terms of analytical, pharmacodynamic, pharmacokinetic, and clinical similarity demonstrated the equivalence of HD201 to trastuzumab. Read More ›

Page 2 of 6